Listen Now

Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients’ health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important. In this eMultipleSclerosis Review Podcast, Dr. Bardia Nourbakhsh from the Johns Hopkins School of Medicine provides clinical insight into reducing the disease burden of these common symptoms. Take our post-test to claim CME credits.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Disease reactivation during and after pregnancy is a challenge facing many women with MS and their clinicians. How can relapses be prevented? What are the benefits of pregnancy planning? What are the risk factors for postpartum MS reactivation? How can they be modified? These are the questions Dr. Kristen Krysko from the University of California San Francisco addresses in this eMultipleSclerosis Review podcast.  Take our post-test to claim CME credits. To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

In this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy. Take our post-test to claim CME credits. To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic. Take our post-test to claim CME credits. To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

The central vein sign. Optical coherence tomography. Serum neurofilament light chain. New research has identified these markers as valuable in discriminating MS from mimicking conditions, and in predicting future disability.In this Issue, Dr. Michael Kornberg and Dr. Elias Sotirchos from the Johns Hopkins University School of Medicine discuss how these advances can impact clinical decision-making to provide better patient care. Take our post-test to claim CME credits. To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Benjamin M. Greenberg, MD, MHS covers the important topic of Incorporating MRI Results in Treatment Decision Making in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Ellen M. Mowry, MD, MCR covers the important topic of New Insights into Lifestyle Modification in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Arun Venkatesan, MD, PhD and Scott Douglas Newsome, DO cover the important topics of personalizing DMT regimens and the risk of medication non-adherence in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.